» Articles » PMID: 16387946

High Prevalence of Abnormal Acid Gastro-oesophageal Reflux in Idiopathic Pulmonary Fibrosis

Overview
Journal Eur Respir J
Specialty Pulmonary Medicine
Date 2006 Jan 3
PMID 16387946
Citations 187
Authors
Affiliations
Soon will be listed here.
Abstract

The aim of this prospective study was to determine the prevalence and characteristics of acid gastro-oesophageal reflux (GER) in patients with idiopathic pulmonary fibrosis (IPF). Sixty-five consecutive patients with well-defined IPF were subjected to 24-h pH monitoring and oesophageal manometry. A total of 133 consecutive patients with intractable asthma and symptoms of GER were used as comparisons. The prevalence of abnormal acid GER in IPF patients was 87%, with 76% and 63% demonstrating abnormal distal and proximal oesophageal acid exposures, respectively. Abnormal acid GER was significantly more common in IPF patients than asthma patients. Only 47% of IPF patients experienced classic GER symptoms. Despite treatment with standard doses of proton pump inhibitors (PPIs), 12 out of 19 patients receiving PPIs during the 24-h pH monitoring had abnormal oesophageal acid exposures by pH probe. There was no correlation between IPF severity and acid GER severity. In conclusion, abnormal acid gastro-oesophageal reflux is highly prevalent, but often clinically occult in patients with idiopathic pulmonary fibrosis. Standard doses of proton pump inhibitors may not suppress the acid gastro-oesophageal reflux in this population. Therefore, further studies are needed to determine if acid abnormal gastro-oesophageal reflux represents an important risk factor for idiopathic pulmonary fibrosis development or progression, and if optimal suppression of acid gastro-oesophageal reflux slows the progression of idiopathic pulmonary fibrosis and/or decreases episodic exacerbations of idiopathic pulmonary fibrosis.

Citing Articles

Non-Pharmacological Management of Idiopathic Pulmonary Fibrosis.

Mullholand J, Grossman C, Perelas A J Clin Med. 2025; 14(4).

PMID: 40004847 PMC: 11856631. DOI: 10.3390/jcm14041317.


The effectiveness and risks of Treating people with Idiopathic Pulmonary fibrosis with the Addition of Lansoprazole (TIPAL): study protocol for a randomised placebo-controlled multicentre clinical trial.

Jones M, Cahn A, Chaudhuri N, Clark A, Forrest I, Hammond M BMJ Open. 2025; 15(2):e088604.

PMID: 39909521 PMC: 11800218. DOI: 10.1136/bmjopen-2024-088604.


Prevalence of Gastroesophageal Reflux in Interstitial Lung Diseases Clinic.

Akhter N, Sumalani K, Chawla D, Rizvi N Cureus. 2025; 16(12):e76454.

PMID: 39866988 PMC: 11769694. DOI: 10.7759/cureus.76454.


Commonly prescribed medications and risk of pneumonia and all-cause mortality in people with idiopathic pulmonary fibrosis: a UK population-based cohort study.

Morgan A, Massen G, Whittaker H, Stewart I, Jenkins G, George P Pneumonia (Nathan). 2025; 17(1):2.

PMID: 39856755 PMC: 11762896. DOI: 10.1186/s41479-024-00155-7.


Examining Cough's Role and Relief Strategies in Interstitial Lung Disease.

Lim C, Khan S, Alsibai T, Sathiyamoorthy G J Clin Med. 2025; 14(1.

PMID: 39797373 PMC: 11721155. DOI: 10.3390/jcm14010291.